VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.

doi:10.1002/ijc.28772

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.

International journal of cancer - 1 Sept 2014

Scartozzi Mario, Faloppi Luca, Svegliati Baroni Gianluca, Loretelli Cristian, Piscaglia Fabio, Iavarone Massimo, Toniutto Pierluigi, Fava Giammarco, De Minicis Samuele, Mandolesi Alessandra, Bianconi Maristella, Giampieri Riccardo, Granito Alessandro, Facchetti Floriana, Bitetto Davide, Marinelli Sara, Venerandi Laura, Vavassori Sara, Gemini Stefano, D'Errico Antonietta, Colombo Massimo, Bolondi Luigi, Bearzi Italo, Benedetti Antonio, Cascinu Stefano

Abstract excerpt

Although new treatment modalities changed the global approach to hepatocellular carcinoma (HCC), this disease still represents a medical challenge. Currently, the therapeutic stronghold is sorafenib, a tyrosine kinase inhibitor (TKI) directed against the vascular endothelial growth factor (VEGF) family. Previous observations suggested that polymorphisms of VEGF and its receptor (VEGFR) genes may regulate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphangiogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Share to Vascular Endothelial Growth Factor C

Share to Vascular Endothelial Growth Factor Receptor-1

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Vascular Endothelial Growth Factor Receptor-3

Source

Open in PubMed

Identifiers

PMID: 24510746
DOI: 10.1002/ijc.28772

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.PMID 24510746Read ↗

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.Semantic proximity Read ↗

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.Semantic proximity Read ↗

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with SorafenibSemantic proximity Read ↗

Genetic biomarkers of sorafenib response in patients with hepatocellular carcinomaSemantic proximity Read ↗

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Semantic proximity Read ↗

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.Semantic proximity Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.Semantic proximity Read ↗

Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.Semantic proximity Read ↗

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.Semantic proximity Read ↗

Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients.Semantic proximity Read ↗

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.